Reinartz G et al. Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. Oncologist 2020; May;25(5):e816-e832. doi: 10.1634/theoncologist.2019-0783
Haentschel M et al. Influence of Biopsy Technique on Molecular Genetic Tumor Characterization in Non-Small Cell Lung Cancer-The Prospective, Randomized, Single-Blinded, Multicenter PROFILER Study Protocol. Diagnostics (Basel) 2020; Jul 6;10(7):459. doi: 10.3390/diagnostics10070459
Boecker W et al. Twenty-Eight Cases of Extraocular Sebaceous Carcinoma: A Correlative Clinicopathological and Immunohistochemical Analysis of Extraocular Sebaceous Carcinomas and Benign Sebaceous Gland Tumors. Am J Dermatopathol 2020; Jun 15. DOI: 10.1097/DAD.0000000000001667
Bermudez M et al. Biological Characterization, Mechanistic Investigation and Structure-Activity Relationships of Chemically Stable TLR2 Antagonists. ChemMedChem 2020; Jul 20;15(14):1364-1371. doi: 10.1002/cmdc.202000060
Buchwalow I et al. Signal amplification in immunohistochemistry: loose-jointed deformable heteropolymeric HRP conjugates vs. linear polymer backbone HRP conjugates. Acta Histochem 2013; Jul;115(6):587-94. doi: 10.1016/j.acthis.2012.12.008
Petersen I et al. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®). Pathol Res Pract 2017; Sept 213(12). doi: 10.1016/j.prp.2017.09.021
Atiakshin D et al. Mast cells and collagen fibrillogenesis. Histochem Cell Biol 2020; Jul;154(1):21-40. DOI: 10.1007/s00418-020-01875-9
Boecker W et al. Multicolor immunofluorescence reveals that p63- and/or K5-positive progenitor cells contribute to normal breast epithelium and usual ductal hyperplasia but not to low-grade intraepithelial neoplasia of the breast. Virchows Arch 2017; May;470(5):493-504. doi: 10.1007/s00428-017-2073-7
Reck M et al. Therapiestandards und Perspektiven beim nichtkleinzelligen Lungenkarzinom im Stadium IV. Onkologie 2012; 35(Suppl 3):10–13. DOI: 10.1159/000338986
Tiemann M et al. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. BMC Res Notes 2020; Mar 7;13(1):139. DOI: 10.1186/s13104-020-04975-w
Atiakshin D et al. Characterization of mast cell populations using different methods for their identification. Histochem Cell Biol 2017; Jun;147(6):683-694. doi: 10.1007/s00418-017-1547-7
Buchwalow I et al. Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. Histochem Cell Biol 2017; Jun;147(6):683-694. DOI: 10.1007/s00418-017-1547-7
Buchwalow I et al. The contribution of Paul Ehrlich to histochemistry: a tribute on the occasion of the centenary of his death. Virchows Arch 2015; Jan;466(1):111-6. doi: 10.1007/s00428-014-1677-4
Berger LA et al. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. J Thorac Oncol 2018; Dec;13(12):e243-e246. DOI: 10.1016/j.jtho.2018.08.2025 I2
Keppens C et al. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018; Jul;20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006
Hallas C et al. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns. Leuk Res 2019; Jan;76:107-111. DOI: 10.1016/j.leukres.2018.10.003
. Multiple immunolabeling with antibodies from the same host species in combination with tyramide signal amplification. Acta Histochem 2018; Jul;120(5):405-411. DOI: 10.1016/j.acthis.2018.05.002
Boecker W et al. Spatial analysis of p63, K5 and K7 defines two groups of progenitor cells that differentially contribute to the maintenance of normal sebaceous glands, extraocular sebaceous carcinoma and benign sebaceous tumors. J Dermatol 2019; Mar;46(3):249-258. DOI: 10.1111/1346-8138.14765
Reinartz G et al. Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). Strahlenther Onkol 2019; DOI: 10.1007/s00066-019-01446-5 Jun;195(6):544-557.
Stenzinger A et al. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. J Thorac Oncol 2020; Jul;15(7):1177-1189. DOI: 10.1016/j.jtho.2020.01.023
Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375
Atiakshin D et al. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol 2018; May;149(5):461-477. DOI: 10.1007/s00418-018-1659-8
Atiakshin D et al. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 2019; Oct;152(4):253-269. DOI: 10.1007/s00418-019-01803-6
Boecker W et al. Adenosquamous Carcinoma of the Pancreas Comprise a Heterogeneous Group of Tumors With the Worst Outcome: A Clinicopathological Analysis of 25 Cases Identified in 562 Pancreatic Carcinomas Resected With Curative Intent. Pancreas 2020; May/Jun 2020;49(5):683-691. doi: 10.1097/MPA.0000000000001548
Schem C et al. One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch 2009; Feb;454(2):203-10. doi: 10.1007/s00428-008-0703-9
Tiemann K et al. Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol 2007; Sep;20(9):955-60. doi: 10.1038/modpathol.3800902
Minckwitz G et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer–results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011; Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0
Tiemann K et al . Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation. Mod Pathol 2006; Nov;19(11):1409-13. doi: 10.1038/modpathol.3800664
Sipos B et al. Lymphatic spread of ductal pancreatic adenocarcinoma is independent of lymphangiogenesis. J Pathol 2005; Nov;207(3):301-12. doi: 10.1002/path.1840
Maass N et al. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Clinical Trial 2014; 87(5):300-10. doi: 10.1159/000365553. Epub 2014 Aug 26
Boecker W et al. Squamous/epidermoid differentiation in normal breast and salivary gland tissues and their corresponding tumors originate from p63/K5/14-positive progenitor cells. Virchows Arch 2015; Jan;466(1):21-36. doi: 10.1007/s00428-014-1671-x. Epub 2014 Oct 26
Boecker W et al. K5/K14-positive cells contribute to salivary gland-like breast tumors with myoepithelial differentiation. Mod Pathol 2013; Aug;26(8):1086-100. doi: 10.1038/modpathol.2013.45
Hallas C et al. BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia. BMC Cancer 2016; Aug 18;16:648. DOI: 10.1186/s12885-016-2707-1
Loibl S et al. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res 2016; Jun 1;22(11):2675-83. DOI: 10.1158/1078-0432.CCR-15-0965
Buchwalow I et al. Oxidative stress and NO generation in the rat pancreatitis induced by pancreatic duct ligation. Acta Histochem 2017; Apr;119(3):252-256. DOI: 10.1016/j.acthis.2017.01.010
Buchwalow I et al. L-arginine-NO-cGMP signalling pathway in pancreatitis. Sci Rep 2013; 2013;3:1899. DOI: 10.1038/srep01899
Boecker W et al. Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept. Histochem Cell Biol 2020; Jul;154(1):97-105. doi: 10.1007/s00418-020-01864-y
Locati LD et al. Immunohistochemical and molecular profile of salivary gland cancer in children. Pediatr Blood Cancer 2017; Sep;64(9). doi: 10.1002/pbc.26468
Boecker W et al. Spatially correlated phenotyping reveals K5-positive luminal progenitor cells and p63-K5/14-positive stem cell-like cells in human breast epithelium. Lab Invest 2018; Aug;98(8):1065-1075. doi: 10.1038/s41374-018-0054-3
Buchwalow I et al. New Insight into the Role of Nitric Oxide Pathways in Pancreas. Acta Histochem Cytochem 2018; Dec 20;51(6):167-172. doi: 10.1267/ahc.1802
Michels S et al. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016; Jan;11(1):122-7. doi: 10.1016/j.jtho.2015.09.016
Menon R et al. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay. J Thorac Oncol 2016; Sep;11(9):e105-7. doi: 10.1016/j.jtho.2016.04.005
Ortiz-Cuaran S et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin Canc Res 2016; Oct 1;22(19):4837-4847. doi: 10.1158/1078-0432.CCR-15-1915
Scheel AH et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117
Latteyer S et al. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine 2016; Dec;54(3):733-741. doi: 10.1007/s12020-016-1080-9
Pajtler KW et al. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 2017; Jan 24;8(4):6730-6741. doi: 10.18632/oncotarget.14268
Michels S et al. ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. NPJ Precis Oncol 2017; Mar 20;1(1):4. doi: 10.1038/s41698-017-0004-3
Gottlieb A et al. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget 2017; Apr 25;8(17):27882-27891. doi: 10.18632/oncotarget.15840
Müller J et al. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol 2017; Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014
Brägelmann J et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep 2017; Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082
Christopoulos P et al. Risk stratification of EGFR + lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020; Oct;148:105-112. doi: 10.1016/j.lungcan.2020.08.007
Schatz S et al. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer. Cancers 2020; Jun 24;12(6):1685. doi: 10.3390/cancers12061685
Bochtler et al. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int J Cancer 2020; Jun 1;146(11):3053-3064. doi: 10.1002/ijc.32882. Epub 2020 Mar 11
Wagener-Ryczek S et al. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors. BMC Cancer 2020; May 12;20(1):408. doi: 10.1186/s12885-020-06920-3
Volz C et al. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. Cell Rep 2020; Apr 28;31(4):107568. doi: 10.1016/j.celrep.2020.107568
Roeper J et al. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC. Oncotarget 2020; Jan 21;11(3):250-264. doi: 10.18632/oncotarget.27430
Thunnissen E et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019; Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023
Michels S et al. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis Oncol 2019; Mar 27;3. doi: 10.1200/PO.18.00210
Michels S et al. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. J Thorac Oncol 2019; Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020.
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215
Frank R et al. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clin Canc Res 2018; Jul 1;24(13):3087-3096. doi: 10.1158/1078-0432.CCR-17-3416
Plenker D et al. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Canc Res 2018; Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001
Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. J Thorac Oncol 2017; Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018